BPI Sports adopts ChromaDex quality verification seal program
Going forward, the "ChromaDex Quality Verified Seal" will be added to the entire line of BPI Sports’ protein powders, assuring that each product has been third-party tested and
Going forward, the "ChromaDex Quality Verified Seal" will be added to the entire line of BPI Sports’ protein powders, assuring that each product has been third-party tested and
The first patients out of a planned total of 600 patients with colorectal cancer treated with chemotherapy have been dosed in the trial. Elsiglutide is a novel GLP-2
"In mid-2013 we announced that we had received notification that our patent and trademarks for the Nyloxin® line of pain relievers had been published in India’s Official Journal,
The patented cotton enhanced insulating materials used in all the packaging products offer soft cushioning thermal protection. The packaging, post-use, is disposable by the customer as ordinary household
The phase 3 clinical program across Asia includes the REDUCER (An Asian, phase 3, multicenter, RandomizEd, Double-blind, placebo-controlled 14-week stUdy of DS-5565 in patients with diabetiC pEripheral neuRopathic
The Silver Spring, Maryland biotech firm is already in the clinic developing targeted oncology treatments, and now, with the initiation of its first preclinical study that will act
The Phase 2a studies, currently underway at Mayo Clinic and the University of Pittsburgh, are evaluating the hemodynamic effects of AIR001 in both acute and exercise conditions, as
This new batch of RP-323 represents a new second-generation compound with improved product usability and stability. Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods
"This patent significantly expands the strength of the VIMOVO patent estate and extends patent protection out to 2031," said Timothy P. Walbert, chairman, president and chief executive officer,
Under the terms of the agreement, Ligand has received an undisclosed initial payment, and is entitled to receive up to $45 million in potential regulatory and commercial milestone